[
  {
    "ts": null,
    "headline": "100 November Sustainable Dividend Dogs: 50 'Safer' And 2 Ideal Buys",
    "summary": "Calvert Research and Management ranked the 100 most sustainable companies based on over 230 ESG indicators. Read here for our picks.",
    "url": "https://finnhub.io/api/news?id=aa8566b16c753efdfa17897ad3b68705ddd124af6791279759da1499746110ed",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731610461,
      "headline": "100 November Sustainable Dividend Dogs: 50 'Safer' And 2 Ideal Buys",
      "id": 131360164,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/171155760/image_171155760.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Calvert Research and Management ranked the 100 most sustainable companies based on over 230 ESG indicators. Read here for our picks.",
      "url": "https://finnhub.io/api/news?id=aa8566b16c753efdfa17897ad3b68705ddd124af6791279759da1499746110ed"
    }
  },
  {
    "ts": null,
    "headline": "United Therapeutics: One To Believe In Despite Competitive Threats",
    "summary": "United Therapeutics' pipeline and Tyvaso DPI drive strong growth. Read why UTHR stock offers substantial upside with promising treatments and cash reserves.",
    "url": "https://finnhub.io/api/news?id=6883885bb29a04c0c7bbc935f583a4d71d8b0a4967bc9a30b33e3b99b6755dbd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731604599,
      "headline": "United Therapeutics: One To Believe In Despite Competitive Threats",
      "id": 131358698,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/954770770/image_954770770.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "United Therapeutics' pipeline and Tyvaso DPI drive strong growth. Read why UTHR stock offers substantial upside with promising treatments and cash reserves.",
      "url": "https://finnhub.io/api/news?id=6883885bb29a04c0c7bbc935f583a4d71d8b0a4967bc9a30b33e3b99b6755dbd"
    }
  },
  {
    "ts": null,
    "headline": "Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics",
    "summary": "Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics",
    "url": "https://finnhub.io/api/news?id=84750e2a708624f1f59cf30547d0a3bca06d21d5d1becb527252bb956a3f95fa",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731603296,
      "headline": "Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics",
      "id": 131414201,
      "image": "",
      "related": "MRK",
      "source": "DowJones",
      "summary": "Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics",
      "url": "https://finnhub.io/api/news?id=84750e2a708624f1f59cf30547d0a3bca06d21d5d1becb527252bb956a3f95fa"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
    "summary": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=4b15b05c230c497fc3c2f2ce9369efb0beb44132dde73b1d46a14d68c6734832",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731602100,
      "headline": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
      "id": 131414225,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=4b15b05c230c497fc3c2f2ce9369efb0beb44132dde73b1d46a14d68c6734832"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Growth Company Fund Q3 2024 Review",
    "summary": "For the third quarter, Fidelity Growth Company Fund's Retail Class shares gained 1.34%, lagging \nthe 3.42% advance of the benchmark. Click here to read more.",
    "url": "https://finnhub.io/api/news?id=1063d4cf1b1f43d376102851ab09375221b2a4df66b12eb494507b97915ecd4c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731588900,
      "headline": "Fidelity Growth Company Fund Q3 2024 Review",
      "id": 131353222,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2071111658/image_2071111658.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "For the third quarter, Fidelity Growth Company Fund's Retail Class shares gained 1.34%, lagging \nthe 3.42% advance of the benchmark. Click here to read more.",
      "url": "https://finnhub.io/api/news?id=1063d4cf1b1f43d376102851ab09375221b2a4df66b12eb494507b97915ecd4c"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Participate in the Jefferies London Healthcare Conference",
    "summary": "RAHWAY, N.J., November 14, 2024--Merck to Participate in the Jefferies London Healthcare Conference",
    "url": "https://finnhub.io/api/news?id=a40cc7bbb94fa69752bdd28a0e4a73385c2eba7dfce8c07ee0157c92a78f5ffa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731586500,
      "headline": "Merck to Participate in the Jefferies London Healthcare Conference",
      "id": 131356118,
      "image": "https://media.zenfs.com/en/business-wire.com/bc063438e110afac171c62c8f5f64825",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., November 14, 2024--Merck to Participate in the Jefferies London Healthcare Conference",
      "url": "https://finnhub.io/api/news?id=a40cc7bbb94fa69752bdd28a0e4a73385c2eba7dfce8c07ee0157c92a78f5ffa"
    }
  },
  {
    "ts": null,
    "headline": "Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.",
    "summary": "RAHWAY, N.J., November 14, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today announced that Merck has entered into an exclusive global license to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova.",
    "url": "https://finnhub.io/api/news?id=643f3a49d04c1ad86522907487f923ccdee176387bef4b0578f8ea8eac8acde3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731584700,
      "headline": "Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.",
      "id": 131356120,
      "image": "https://media.zenfs.com/en/business-wire.com/4565f2acfa25787a6153744ca40fdf43",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., November 14, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today announced that Merck has entered into an exclusive global license to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova.",
      "url": "https://finnhub.io/api/news?id=643f3a49d04c1ad86522907487f923ccdee176387bef4b0578f8ea8eac8acde3"
    }
  },
  {
    "ts": null,
    "headline": "Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy",
    "summary": "The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that recently bested Keytruda in a clinical trial.",
    "url": "https://finnhub.io/api/news?id=56175497764960f8aa77be5adfcbde6556cd9e78ea73239c11f7e2be65110c64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731580740,
      "headline": "Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy",
      "id": 131356122,
      "image": "https://imgproxy.divecdn.com/7j3L9zoOKIsosYks1PWD7yJsHPPFKeNLehPX235r8wA/g:ce/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTU2MjkzMTgzX2gwcG5SMlEuanBn.webp",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that recently bested Keytruda in a clinical trial.",
      "url": "https://finnhub.io/api/news?id=56175497764960f8aa77be5adfcbde6556cd9e78ea73239c11f7e2be65110c64"
    }
  },
  {
    "ts": null,
    "headline": "Merck: acquires exclusive license from LaNova Medicines",
    "summary": "Merck announces that it has acquired an exclusive license from LaNova Medicines to develop, manufacture and commercialize LM-299, a bispecific antibody from LaNova.This agreement enhances our growing...",
    "url": "https://finnhub.io/api/news?id=23905a57a9bc5e9bf9105ff1ac22473ed666917cc3d4259a36637426bccfee04",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731579375,
      "headline": "Merck: acquires exclusive license from LaNova Medicines",
      "id": 131349561,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announces that it has acquired an exclusive license from LaNova Medicines to develop, manufacture and commercialize LM-299, a bispecific antibody from LaNova.This agreement enhances our growing...",
      "url": "https://finnhub.io/api/news?id=23905a57a9bc5e9bf9105ff1ac22473ed666917cc3d4259a36637426bccfee04"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks",
    "summary": "Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite recent volatility.",
    "url": "https://finnhub.io/api/news?id=9f2de013161d55bf4cc737652a7ccc9fae1071b127322c8d1f99225c5a81aa33",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731575824,
      "headline": "Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks",
      "id": 131348835,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1297651437/image_1297651437.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite recent volatility.",
      "url": "https://finnhub.io/api/news?id=9f2de013161d55bf4cc737652a7ccc9fae1071b127322c8d1f99225c5a81aa33"
    }
  },
  {
    "ts": null,
    "headline": "Immutep ADRs Climb on Positive Efti Trial Results",
    "summary": "Immutep ADRs Climb on Positive Efti Trial Results",
    "url": "https://finnhub.io/api/news?id=d558111ef4ea5cea5c7270b73f87519c27c53e4d0890f7509aff9f6d8faedf4a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731575400,
      "headline": "Immutep ADRs Climb on Positive Efti Trial Results",
      "id": 131414226,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Immutep ADRs Climb on Positive Efti Trial Results",
      "url": "https://finnhub.io/api/news?id=d558111ef4ea5cea5c7270b73f87519c27c53e4d0890f7509aff9f6d8faedf4a"
    }
  },
  {
    "ts": null,
    "headline": "Merck in Cancer Licensing Pact With LaNova Medicines",
    "summary": "By Colin Kellaher Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company. Merck on Thursday...",
    "url": "https://finnhub.io/api/news?id=84dbd6896f44391405aa1b7c63360a329bb6ec132e12900f7c278381287de11d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731571035,
      "headline": "Merck in Cancer Licensing Pact With LaNova Medicines",
      "id": 131346960,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company. Merck on Thursday...",
      "url": "https://finnhub.io/api/news?id=84dbd6896f44391405aa1b7c63360a329bb6ec132e12900f7c278381287de11d"
    }
  }
]